Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COSTEM 2021 | Optimizing transplantation outcomes for patients with AML

Andreas Burchert • 15 Oct 2021
COSTEM 2021
Acute Myeloid Leukemia Leukemia Gilteritinib Ivosidenib Midostaurin Venetoclax

Andreas Burchert, MD, University of Marburg, Marburg, Germany, outlines the latest data on the optimization of transplantation outcomes for patients with acute myeloid leukemia. Dr Burchert describes how the risk of relapse currently presents the greatest challenge in the field and comments on the need to improve the rate and depth of remissions prior to transplantation. In the post-transplant setting, Dr Burchert highlights the need to have highly tolerable therapeutic options available. This interview took place at the 6th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM), which took place virtually.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Andreas Burchert

Post-transplant maintenance strategies in AML
5:00
Post-transplant maintenance strategies in AML
Andreas Burchert • 15 Oct 2021
Sorafenib as SOC maintenance after allo-transplant in FLT3+ AML
2:57
Sorafenib as SOC maintenance after allo-transplant in FLT3+ AML
Andreas Burchert • 15 Oct 2021
Sorafenib for FLT3-ITD-positive AML
2:23
Sorafenib for FLT3-ITD-positive AML
Andreas Burchert • 3 Dec 2018
The future of AML therapy
1:44
The future of AML therapy
Andreas Burchert • 3 Jan 2019

Related Videos

Addressing changes to genomic prognostic markers in CLL beyond the chemotherapy era
4:04
Addressing changes to genomic prognostic markers in CLL beyond the chemotherapy era
Anna Schuh • 16 Oct 2026
Understanding the CLL genome: current knowledge and remaining gaps
3:39
Understanding the CLL genome: current knowledge and remaining gaps
Anna Schuh • 16 Oct 2026
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
2:00
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
Alexey Danilov • 16 Oct 2026
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
3:39
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
Marta Coscia • 16 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals